TOTAL VOLUME:
$134b
24H VOL:
$103,397,351
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,410,176,180
399,592
Markets across
30,097
events
MATCHED EVENTS:
2,622
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
FDA approves Vera Therapeutics' Atacicept?
- Polymarket
FDA approves Vera Therapeutics' Atacicept? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolved Jul 7, 2026
Closed: Jul 6, 8:00 PM EST
Polymarket
Description
As of market creation, the FDA's expected decision date for the specified application is July 7, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Vera Therapeutics's Atacicept as a treatment for IgA nephropathy in adults by July 21, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is July 7, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Vera Therapeutics's Atacicept as a treatment for IgA nephropathy in adults by July 21, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds often diverge from traditional analyst forecasts because they incorporate real-time information and financial incentives for accuracy. While Wall Street analysts may issue periodic reports on Vera Therapeutics' pipeline prospects, this market aggregates the views of traders who have skin in the game. Analysts typically focus on broader commercial potential and clinical trial timelines, whereas prediction markets distill those signals into a single probability. Comparing the two can reveal whether the market is pricing in more optimism or caution than the consensus view.
On Polymarket, this market is priced through an automated market maker that allows traders to buy or sell shares representing approval or rejection. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The price of each outcome reflects supply and demand; as more traders bet on approval, the price rises, and vice versa. Shares are denominated in cents, so a price of 99 cents means the market is assigning roughly 99% probability to FDA approval. You can enter or exit positions at any time before the market closes, with the current price always visible on the order book.
This market resolves around Jul 7, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The resolution hinges on whether the FDA formally approves Atacicept for its intended indication. Once the agency issues an official decision—whether approval, rejection, or a request for additional data—the market will settle accordingly. Traders should monitor FDA announcements, press releases from Vera Therapeutics, and regulatory filings to anticipate the likely timing and direction of the decision.
Key catalysts include clinical trial data releases, FDA meeting announcements, and regulatory feedback letters that signal the agency's stance on Atacicept. Positive Phase 3 results or favorable comments from FDA reviewers would likely push odds higher, while safety concerns or requests for additional studies could drive them lower. Company earnings calls and investor presentations may also reveal new timelines or strategic updates. Broader biotech sentiment, changes in FDA leadership or policy, and competitive approvals in the same therapeutic area could all influence trader positioning in this market.
